Currently Viewing:

GLP-1 Drugs Not Associated With Increased Risk of Diabetic Retinopathy, Study Finds

Mary Caffrey
The analysis of patient records found no elevated risk of retinopathy among those using glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes.
Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with increased risk of incident diabetic retinopathy, according to a study published in Diabetes Care.

GLP-1 receptor agonists (RAs) lower blood sugar levels by promoting insulin secretion. Patients who use these drugs to treat type 2 diabetes not only see improved glycemic control but may also lose weight. In fact, one GLP-1 therapy, liraglutide, is approved in a formulation to treat obesity. Studies have also been published showing cardiovascular benefits for liraglutide and semaglutide, and FDA granted a cardiovascular indication for liraglutide last year.

Read About Once-Weekly Semaglutide

The SUSTAIN-6 study had pointed to a possible worsening of retinopathy with semaglutide, although this was not borne out in the SUSTAIN-7 trial prior to approval. The claims study published this week evaluated data from 77,115 patients in the United Kingdom who had type 2 diabetes (T2D) and began taking therapies between January 2007 and September 2015. Researchers compared those taking GLP-1 RAs with those taking 2 or more oral antidiabetic drugs and, in a separate analysis, compared those taking GLP-1 RAs with those taking insulin.

During 245,825 person-years of follow-up, 10,763 patients were newly diagnosed with diabetic retinopathy. Compared with those taking 2 or more oral drugs, the risk of retinopathy among those taking the GLP-1 class was the same (hazard ratio [HR], 1.00; 95% CI, 0.85-1.17). Those taking the GLP-1 class had a 33% reduced risk of retinopathy compared with those taking insulin (HR, 0.67; 95% CI, 0.51-0.90). The authors wrote that the apparent lower risk of diabetic retinopathy may be due to residual confounding.


Douros A, Filion KB, Yin H, et al. Glucagon-like peptide-1 receptor agonists and the risk of incident diabetic retinopathy [published online August 27, 2018]. Diabetes Care. 2018. doi: 10.2337/dc17-2280.

Related Articles

Dr Todd Hobbs Discusses the Advantages of Semaglutide in Type 2 Diabetes
Semaglutide Produces Significant, Sustained Weight Loss for Adults With Obesity in Phase 2 Trial
JAMA Comparison: SGLT2 Inhibitors, GLP-1 Agonists Offer Lower Mortality in Type 2 Diabetes
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up